SAHPRA and Pharma Industry Strengthen Regulatory Compliance to Safeguard Public Health
SAHPRA's Inspectorate Senior Manager, Lebohang Mazibuko, at the Inspectorate Workshop.

SAHPRA and Pharma Industry Strengthen Regulatory Compliance to Safeguard Public Health

Johannesburg, 18 November 2026 – The South African Health Products Regulatory Authority (SAHPRA) convened an Inspectorate Workshop on 13 November 2026 at the Galagher Convention Centre, Johannesburg, bringing together pharmaceutical industry representatives to strengthen regulatory compliance and uphold quality, safety, and efficacy (QSE) standards in the interest of public health.

Held under the theme “Strengthening Compliance, Protecting Patients,” the workshop highlighted key regulatory compliance challenges in the manufacturing and handling of health products, emphasising the importance maintaining rigorous quality standards throughout the production and distribution processes to safeguard public health.

SAHPRA emphasized that effective quality management systems (QMS) must extend beyond routine documentation and be embedded in daily operations. SAHPRA and industry share a responsibility to ensure that these systems function effectively, uphold regulatory standards and prioritise patient safety across the health products value chain.

In her opening remarks, SAHPRA’s Chief Regulatory Officer, Tammy Gopal, emphasised the importance of regulatory compliance as a shared responsibility in safeguarding public health and ensuring the safety, quality and efficacy of health products.

“We are here to engage with industry, provide regulatory guidance and identify sustainable solutions,” said Gopal. “Patient safety remains central to SAHPRA’s mandate, making compliance with quality, safety and efficacy standards non-negotiable.

To guide the discussions, SAHPRA presented regulatory trends and common compliance findings observed over the past three years. SAHPRA Senior Manager for Inspectorate, Lebohang Mazibuko, highlighted the real-world impact of regulatory excellence on everyday South Africans.

“An elderly woman in Lusikisiki in the Eastern Cape or an aunt in Kabokweni in Mpumalanga, should be able to take their medicines with confidence, knowing that we have collectively ensured their safety,” said Ms Mazibuko. “This requires rigorous processes and consistent adherence to quality and safety standards throughout the health products value chain.”

Moving forward, SAHPRA urged industry partners to use past inspection findings as a starting point for continuous improvement. Industry stakeholders were encouraged to adopt a structured, phased approach to resolving issues that could pose safety risks, focusing on thorough investigations, targeted mitigation plans, and robust corrective and preventative actions (CAPA).